Strategic Partnership to Accelerate Immunotherapy Innovation
OSE Immunotherapeutics has entered a strategic partnership with Inserm Transfert and Nantes University to source, mature, and industrialize early-stage...
Organogenesis Provides Update on Phase 3 Renu® Study
Organogenesis reported that its second Phase 3 randomized controlled trial of ReNu, a cryopreserved amniotic suspension allograft for symptomatic...
Kraig Labs Expands Production for Large International Order
Kraig Biocraft Laboratories has opened a second Southeast Asian rearing center for its engineered silkworms, bringing parallel production online...
BioXcel Therapeutics Announces Positive Topline Results from Phase 3 SERENITY Trial of BXCL501
BioXcel Therapeutics reported that its pivotal Phase 3 SERENITY at-home study met its primary endpoint, demonstrating that a 120...
Quell Therapeutics Forms World-Class Scientific Advisory Board
Quell Therapeutics has convened a new scientific advisory board to steer its engineered T-regulatory cell therapy portfolio, adding heavyweight...
Seres Therapeutics at H.C. Wainwright 27th Annual Global Investment Conference
Seres Therapeutics will present a company overview at the H.C. Wainwright Global Investment Conference in New York on September...
Mesoblast Reports Mixed Financial Results, Corporate Update Webcast
Mesoblast will host a webcast to review operational highlights and full-year results for the period ended June 30, 2025,...
Medicinova Completes COMBAT-ALS Trial Enrollment
MediciNova has completed target enrollment in COMBAT-ALS, its Phase 2b/3 clinical trial of MN-166 (ibudilast), across sites in the...
Mesoblast Triumphs With First FDA Approval, Ryoncil Launch
Mesoblast has closed its fiscal year with the first FDA-approved mesenchymal stromal cell therapy on the U.S. market and...
Codexis Will Participate in Cantor Global Healthcare Conf
Codexis will present at the Cantor Global Healthcare Conference in New York on September 4, 2025, with a webcast...